Marval Advises Takeda in the Sale of Hepatalgina to Laboratorio Elea-Phoenix

On Friday, June 12, Takeda Pharma S.A sold the Hepatalgina business, Argentina’s leading product for decades, to Laboratorio Elea-Phoenix S.A.. The transaction included the transfer of a working factory, employees, trademarks and product marketing authorization certificates. The price of the transaction was of USD 7 million.
 
The transaction was carried out during the COVID-19 pandemic while a mandatory quarantine was in force; it therefore required coordinated, innovative and collaborative legal work to close successfully.
 
Marval O’Farrell Mairal was external legal counsel for Takeda through partners Miguel del Pino and Martín Mosteirin, and associates Pilar Etcheverry Boneo, Inés Pallitto Bernabe and Matías Koch. 

Federico Fernández Zavalía was in-house counsel for Takeda.
 
Lorena Aimó was in-house counsel for Elea-Phoenix.